drugset / Trial / NCT00595985
Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and tolerability of sorafenib as second line treatment in patients with Advanced or Metastatic Gastric Cancer (A/MGC).
Timeline
- Start
- 2007-07
- Primary completion
- 2009-01
- Completion
- 2009-01
Outcome
Outcome not reported
Stopped: “low response rate, no evidence of PFS or OS improved.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | — |